Younger age is generally associated with better health and longer life expectancy. However, new findings from the international IRONMAN registry suggest a different pattern in advanced prostate cancer: men diagnosed at age 55 or younger may have worse survival outcomes than those diagnosed at middle or older ages. The analysis included 4,332 patients from 15 […]
New biomarker data provide additional evidence of the preliminary activity of ABBV-969, an investigational antibody-drug conjugate (ADC) designed to target both PSMA and STEAP1 in metastatic castration-resistant prostate cancer (mCRPC). The findings come from the ongoing Phase 1 study, involving 49 heavily pretreated patients who had received a median of five previous treatment lines. Most […]
New results presented at EANM 2026 provide further evidence of the preliminary clinical activity of ²²⁵Ac-LNC1011, an experimental PSMA-targeted alpha radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). We have previously discussed this therapy in this post. Following the initial results, the new prospective study includes 15 patients previously treated with androgen receptor pathway inhibitors […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Research is accelerating, and we have more good news to share with you. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it […]
A randomised phase 2 trial published in Nature Medicine has investigated whether adding the PARP inhibitor talazoparib to enzalutamide and androgen deprivation therapy (ADT) can improve outcomes in men with high-volume metastatic hormone-sensitive prostate cancer (mHSPC), regardless of their homologous recombination repair (HRR) mutation status. The study, known as ZZ-FIRST enrolled 54 patients across eight […]
A new preclinical study published in the Journal of Nuclear Medicine has investigated rhPSMA-10.1, a radiohybrid compound designed to combine PET imaging with targeted alpha therapy for prostate cancer. The approach uses two closely related versions of the same PSMA-targeting molecule: ¹⁸F/La-rhPSMA-10.1 for PET imaging and ²²⁵Ac-rhPSMA-10.1 for treatment. Their similar chemical properties could allow […]
A newly registered phase 2 clinical trial will investigate whether combining tinengotinib (TT-00420) with darolutamide or enzalutamide can improve disease control in men with metastatic castration-resistant prostate cancer (mCRPC). Tinengotinib is an oral multikinase inhibitor targeting several pathways involved in cancer growth and survival, including FGFR, JAK, VEGFR and Aurora kinases. Unlike darolutamide and enzalutamide, […]
A new Phase 1 clinical trial will investigate ITR-251, an experimental inhibitor of monoamine oxidase A (MAO-A), as a potential treatment for advanced solid tumours and metastatic castration-resistant prostate cancer (mCRPC). What makes this investigation unusual is its molecular target. MAO-A is an enzyme best known for breaking down neurotransmitters and other monoamines. However, research […]
A newly registered phase 1/2 clinical trial will investigate whether combining two immunotherapies with complementary mechanisms can improve treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). The study, known as JET-201, plans to enrol 107 patients in the United States and South Korea. The combination brings together pasritamig (JNJ-78278343), a bispecific antibody designed […]
Longer follow-up from the randomized phase 2 LUNAR trial suggests that PSMA-targeted radioligand therapy may do more than simply delay progression when used early in men with oligorecurrent hormone-sensitive prostate cancer. LUNAR enrolled 92 men whose prostate cancer had returned after previous treatment, with one to five metastases visible on PSMA PET/CT. Importantly, patients were […]